- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.03. | Novartis to acquire Excellergy for $2bn upfront | ||
| 27.03. | Simulations Plus and three pharma companies collaborate on AI-driven drug development | ||
| 26.03. | Corcept's first-in-class ovarian cancer drug gains FDA approval | ||
| 26.03. | FDA opens door to feedback on 'unclear' national priority voucher pathway | ||
| 26.03. | Cognito Therapeutics and Ochsner partner for new brain health approaches | ||
| 26.03. | Daiichi Sankyo and Tempus AI collaborate on ADC clinical development | ||
| 25.03. | UCB banks on Georgia for $2bn biologics manufacturing facility | ||
| 25.03. | MSD spends $6.7bn to buy Terns Pharmaceuticals in cancer pipeline reinforcement | ||
| 25.03. | Viz.ai and Alnylam to advance earlier identification of cardiac amyloidosis | ||
| 25.03. | MSD and Quotient collaborate on IBD drug targets | ||
| 24.03. | Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout | ||
| 24.03. | Monash University and ClinChoice partner on new therapies development | ||
| 24.03. | Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody | ||
| 23.03. | Earendil Labs lands $787m to fund biologics development push | ||
| 23.03. | ImmunityBio receives Macau approval for Anktiva combo therapy | ||
| 23.03. | BMS secures FDA and EC approvals for Opdivo in Hodgkin Lymphoma | ||
| 20.03. | Novo Nordisk's Wegovy HD secures FDA greenlight amid patent expiries | ||
| 20.03. | Novartis to acquire SNV4818 from Synnovation | ||
| 20.03. | Congruence secures $39.5m to advance small molecule correctors pipeline | ||
| 20.03. | J&J wins FDA approval for Icotyde to enter psoriasis pill market | ||
| 19.03. | MHRA and NICE launch aligned pathway for faster medicine regulation | ||
| 19.03. | Quintessence debuts first 'living' artificial cell for CGT bio-separation | ||
| 19.03. | Huntington's gene therapy research has reached a turning point, expert says | ||
| 18.03. | Calls for change as access to cell and gene therapies in the Netherlands falls short | ||
| 18.03. | Excalipoint debuts with $68.7m to progress TCE pipeline |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.